A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
This pre-specified analysis of DAPA-CKD assessed the impact of sodium-glucose cotransporter 2 inhibition on abrupt declines in kidney function in high-risk patients based on having chronic kidney disease (CKD) and substantial albuminuria. DAPA-CKD was a randomized, double-blind, placebo-controlled trial that had a median follow-up of 2.4 years. Adults with CKD (urinary albumin-to-creatinine ratio 200–5000 mg/g and estimated glomerular filtration rate 25–75 mL/min/1.73m 2 ) were randomized to dapagliflozin 10 mg/day matched to placebo (2152 individuals each). An abrupt decline in kidney function was defined as a pre-specified endpoint of doubling of serum creatinine between two subsequent study visits. We also assessed a post-hoc analysis of investigator-reported acute kidney injury–related serious adverse events. Doubling of serum creatinine between two subsequent visits (median time-interval 100 days) occurred in 63 (2.9%) and 91 (4.2%) participants in the dapagliflozin and placebo groups, respectively (hazard ratio 0.68 [95% confidence interval 0.49, 0.94]). Accounting for the competing risk of mortality did not alter our findings. There was no heterogeneity in the effect of dapagliflozin on abrupt declines in kidney function based on baseline subgroups. Acute kidney injury–related serious adverse events were not significantly different and occurred in 52 (2.5%) and 69 (3.2%) participants in the dapagliflozin and placebo groups, respectively (0.77 [0.54, 1.10]). Thus, in patients with CKD and substantial albuminuria, dapagliflozin reduced the risk of abrupt declines in kidney function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationFitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893 · cited 2×
“Long-term safety data from other cardiovascular outcome trials (starting with the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients [EMPA-REG OUTCOME] and subsequently endorsed by other cardiovascular outcome trials) have demonstrated the safety of SGLT2 inhibitors with respect to A…”
BackgroundSelf-citationAcute kidney injury episodes and chronic kidney disease risk in diabetes mellitus
Thakar, C. V., Christianson, A., Himmelfarb, J., & Leonard, A. C. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01120211 · Cited by 485
James, M. T., Grams, M. E., Woodward, M., Elley, C. R., Green, J. A., Wheeler, D. C., de Jong, P., Gansevoort, R. T., Levey, A. S., Warnock, D. G., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.02.338 · Cited by 309 · cited 2×
“Moreover, AKI is associated with adverse clinical outcomes including dialysis, cardiovascular disease and mortality, especially in patients with diabetes and in those with significant albuminuria.(4,5) Large randomized controlled trials in patients with type 2 diabetes have shown that sodium-glucose co-transporter 2 (…”
BackgroundSelf-citationJhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050391 · Cited by 307 · cited 1×
“trial in which dapagliflozin reduced the risk of AKI, defined as a doubling of serum creatinine between two subsequent visits, by 44%.(17) Finally, this signal of kidney safety around the issue Jo ur al Pr e-p roo f”
BackgroundSelf-citationCherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30162-5 · Cited by 283 · cited 1×
“73m(2).(12,13) Prior to the availability of data from cardiovascular safety trials, there was concern among some clinicians that the abrupt rise in creatinine reflected a possible signal of harm related to AKI which has a deleterious effect on survival - an effect that is amplified in the presence of CKD and increased…”
Self-citationKraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.031 · Cited by 219
Self-citationAcute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
Nadkarni, G. N., Ferrandino, R., Chang, A., Surapaneni, A., Chauhan, K., Poojary, P., Saha, A., Ferket, B., Grams, M. E., & Coca, S. G. (2017) · Diabetes Care · doi:10.2337/dc17-1011 · Cited by 188
Research works printed but not linked: 21
- Susantitaphong, 2013, World incidence of AKI: a meta-analysis, Clin J Am Soc Nephrol, 8, 1482, 10.2215/CJN.00710113 · DOI · Paper page
- Coca, 2012, Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis, Kidney Int, 81, 442, 10.1038/ki.2011.379 · DOI · Paper page
- Vallon, 2014, Do tubular changes in the diabetic kidney affect the susceptibility to acute kidney injury?, Nephron Clin Pract, 127, 133, 10.1159/000363554 · DOI
- Perlman, 2017, Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database, Nutr Metab Cardiovasc Dis, 27, 1108, 10.1016/j.numecd.2017.10.011 · DOI
- van Raalte, 2018, Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials, Kidney Int, 94, 459, 10.1016/j.kint.2018.05.026 · DOI · Paper page
- Sridhar VS, Tuttle KR, Cherney DZI. We can finally stop worrying about SGLT2 inhibitors and acute kidney injury. Am J Kidney Dis. 2020;76:454–456. · DOI
- VanderWeele, 2011, Causal mediation analysis with survival data, Epidemiology, 22, 582, 10.1097/EDE.0b013e31821db37e · DOI · Paper page
- Valeri, 2015, SAS macro for causal mediation analysis with survival data, Epidemiology, 26, e23, 10.1097/EDE.0000000000000253 · DOI · Paper page
- 2020, KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease, Kidney Int, 98, S1, 10.1016/j.kint.2020.06.019 · DOI · Paper page
- Zhao, 2020, Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury, Clin J Am Soc Nephrol, 16, 70, 10.2215/CJN.11220720 · DOI · Paper page
- Iskander, 2020, Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study, CMAJ, 192, E351, 10.1503/cmaj.191283 · DOI · Paper page
- Rampersad, 2020, Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study, Am J Kidney Dis, 76, 471, 10.1053/j.ajkd.2020.03.019 · DOI
- Cahn, 2019, Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis, Diabetes Obes Metab, 21, 340, 10.1111/dom.13532 · DOI · Paper page
- Aggarwal, 2021, Generalizability of DAPA-CKD to the United States, Circ Cardiovasc Qual Outcomes, 14, 10.1161/CIRCOUTCOMES.121.007875 · DOI
- Kosiborod, 2021, Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: design and rationale for the DARE-19 study, Diabetes Obes Metab, 23, 886, 10.1111/dom.14296 · DOI
- O'Neill, 2015, Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats, Am J Physiol Renal Physiol, 309, F227, 10.1152/ajprenal.00689.2014 · DOI · Paper page
- Nassif, 2021, Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF Trial, Circulation, 143, 1673, 10.1161/CIRCULATIONAHA.120.052503 · DOI · Paper page
- Zhang, 2018, A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice, Kidney Int, 94, 524, 10.1016/j.kint.2018.05.002 · DOI · Paper page
- Chang, 2016, Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury, PLoS One, 11
- Johnson, 2018, Rethinking progression of CKD as a process of punctuated equilibrium, Nat Rev Nephrol, 14, 411, 10.1038/s41581-018-0016-4 · doi:10.1038/s41581-018-0016-4
- Lawler, 2021, Changes in cardiovascular biomarkers associated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes, Diabetes Care, 44, e45, 10.2337/dc20-2265 · DOI
Cited by
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citationHypertension as Cardiovascular Risk Factor in Chronic Kidney Disease
Burnier, M., & Damianaki, A. (2023) · Circulation Research · doi:10.1161/circresaha.122.321762 · Cited by 400
Heerspink, H. J. L., Apperloo, E., Davies, M., Dicker, D., Kandler, K., Rosenstock, J., Sørrig, R., Lawson, J., Zeuthen, N., & Cherney, D. (2023) · Diabetes Care · doi:10.2337/dc22-1889 · Cited by 98
Self-citationMavrakanas, T. A., Tsoukas, M. A., Brophy, J. M., Sharma, A., & Gariani, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-42989-z · Cited by 99
“Finally, dapagliflozin was found to be associated with lower incidence of abrupt renal function decline, defined as doubling of serum creatinine from most recent value, suggesting a protective effect against AKI 30 .”
Influential
Metadata
- Authors
- Heerspink, H. J. L., Cherney, D., Postmus, D., Stefánsson, B. V., Chertow, G. M., Dwyer, J. P., Greene, T., Kosiborod, M., Langkilde, A. M., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., Toto, R. D., Wheeler, D. C., Heerspink, H. J. L., Wheeler, D. C., Chertow, G., Correa-Rotter, R., Greene, T., Hou, F. F., McMurray, J., Rossing, P., Toto, R., Stefansson, B., Langkilde, A. M., Maffei, L. E., Raffaele, P., Solis, S. E., Arias, C. A., Aizenberg, D., Luquez, C., Zaidman, C., Cluigt, N., Mayer, M., Alvarisqueta, A., Wassermann, A., Maldonado, R., Bittar, J., Maurich, M., Gaite, L. E., Garcia, N., Sivak, L., Ramallo, P. O., Santos, J. C., Garcia Duran, R., Oddino, J. A., Maranon, A., Maia, L. N., Avila, D. D., Barros, E. J. G., Vidotti, M. H., Panarotto, D., Noronha, I. D. L., Turatti, L. A. A., Deboni, L., Canziani, M. E., Riella, M. C., Bacci, M. R., Paschoalin, R. P., Franco, R. J., Goldani, J. C., St-Amour, E., Steele, A. W., Goldenberg, R., Pandeya, S., Bajaj, H., Cherney, D., Kaiser, S. M., Conway, J. R., Chow, S. S., Bailey, G., Lafrance, J., Winterstein, J., Cournoyer, S., Gaudet, D., Madore, F., Houlden, R. L., Dowell, A., Langlois, M., Muirhead, N., Khandwala, H., Levin, A., Hou, F., Xue, Y., Zuo, L., Hao, C., Ni, Z., Xing, C., Chen, N., Dong, Y., Zhou, R., Xiao, X., Zou, Y., Wang, C., Liu, B., Chen, Q., Lin, M., Luo, Q., Zhang, D., Wang, J., Chen, M., Wang, X., Zhong, A., Dong, J., Zhu, C., Yan, T., Luo, P., Ren, Y., Pai, P., Li, D., Zhang, R., Zhang, J., Xu, M., Zhuang, Y., Kong, Y., Yao, X., Peng, X., Persson, F. I., Hansen, T. K., Borg, R., Pedersen Bjergaard, U., Hansen, D., Hornum, M., Haller, H., Klausmann, G., Tschope, D., Kruger, T., Gross, P., Hugo, C., Obermuller, N., Rose, L., Mertens, P., Zeller-Stefan, H., Fritsche, A., Renders, L., Muller, J., Budde, K., Schroppel, B., Wittmann, I., Voros, P., Dudas, M., Tabak, G. A., Kirschner, R., Letoha, A., Balku, I., Hermanyi, Z., Zakar, G., Mezei, I., Nagy, G. G., Lippai, J., Nemeth, A., Khullar, D., Gowdaiah, P. K., Fernando Mervin, E., Rao, V. A., Dewan, D., Goplani, K., Maddi, V. S. K., Vyawahare, M. S., Pulichikkat, R. K., Pandey, R., Sonkar, S. K., Gupta, V. K., Agarwal, S., Asirvatham, A. J., Ignatius, A., Chaubey, S., Melemadathil, S., Alva, H., Kadam, Y., Shimizu, H., Sueyoshi, A., Takeoka, H., Abe, Y., Imai, T., Onishi, Y., Fujita, Y., Tokita, Y., Oura, M., Makita, Y., Idogaki, A., Koyama, R., Kikuchi, H., Kashihara, N., Hayashi, T., Ando, Y., Tanaka, T., Shimizu, M., Hidaka, S., Gohda, T., Tamura, K., Abe, M., Kamijo, Y., Imasawa, T., Takahashi, Y., Nakayama, M., Tomita, M., Hirano, F., Nakayama, M., Fukushima, Y., Kiyosue, A., Kurioka, S., Imai, E., Kitagawa, K., Waki, M., Wada, J., Uehara, K., Iwatani, H., Ota, K., Shibazaki, S., Tamura, K., Katayama, K., Narita, I., Iinuma, M., Matsueda, S., Sasaki, S., Yokochi, A., Tsukamoto, T., Yoshimura, T., Kang, S., Lee, S., Lim, C. S., Chin, H., Joo, K. W., Han, S. Y., Chang, T. I., Park, S., Park, H., Park, C. W., Han, B. G., Cha, D. R., Yoon, S. A., Kim, W., Kim, S. W., Ryu, D., Correa Rotter, R., Irizar Santana, S. S., Hernandez Llamas, G., Valdez Ortiz, R., Secchi Nicolas, N. C., Gonzalez Galvez, G., Lazcano Soto, J. R., Bochicchio Riccardelli, T., Bayram Llamas, E. A., Ramos Ibarra, D. R., Melo, M. G. S., Gonzalez Gonzalez, J. G., Sanchez Mijangos, J. H., Madero Robalo, M., Garcia Castillo, A., Manrique, H. A., Farfan, J. C., Vargas, R., Valdivia, A., Dextre, A., Escudero, E., Calderon Ticona, J. R., Gonzales, L., Villena, J., Leon, L., Molina, G., Saavedra, A., Garrido, E., Arbanil, H., Vargas Marquez, S., Rodriguez, J., Isidto, R., Villaflor, A. J., Gumba, M. A., Tirador, L., Comia, R. S., Sy, R. A., Guanzon, M. L. V. V., Aquitania, G., De Asis, N. C., Silva, A. A., Romero, C. M., Lim, M. E., Danguilan, R. A., Nowicki, M., Rudzki, H., Landa, K., Kucharczyk-Bauman, I., Gogola-Migdal, B., Golski, M., Olech-Cudzik, A., Stompor, T., Szczepanik, T., Miklaszewicz, B., Sciborski, R., Kuzniewski, M., Ciechanowski, K., Wronska, D., Klatko, W., Mazur, S., Popenda, G., Myslicki, M., Bolieva, L. Z., Berns, S., Galyavich, A., Abissova, T., Karpova, I., Platonov, D., Koziolova, N., Kvitkova, L., Nilk, R., Medina, T., Rebrov, A., Rossovskaya, M., Sinitsina, I., Vishneva, E., Zagidullin, N., Novikova, T., Krasnopeeva, N., Magnitskaya, O., Antropenko, N., Batiushin, M., Escudero Quesada, V., Barrios Barrea, C., Espinel Garauz, E., Cruzado Garrit, J. M., Morales Portillo, C., Gorriz Teruel, J. L., Cigarran Guldris, S., Praga Terente, M., Robles Perez-Monteoliva, N. R., Tinahones Madueno, F. J., Soto Gonzalez, A., Diaz Rodriguez, C., Furuland, H., Saeed, A., Dreja, K., Spaak, J., Bruchfeld, A., Kolesnyk, M., Levchenko, O., Pyvovarova, N., Stus, V., Doretskyy, V., Korobova, N., Horoshko, O., Katerenchuk, I., Mostovoy, Y. M., Orynchak, M., Legun, O., Dudar, I., Bilchenko, O., Andreychyn, S., Levchenko, A., Zub, L., Tereshchenko, N., Topchii, I., Ostapenko, T., Bezuglova, S., Kopytsya, M., Turenko, O., Mark, P., Barratt, J., Bhandari, S., Fraser, D., Kalra, P., Kon, S. P., Mccafferty, K., Mikhail, A., Kon, S. P., Alvarado, O. P., Anderson, R., Andrawis, N. S., Arif, A., Benjamin, S. A., Bueso, G., Busch, R. S., Carr, K. W., Crawford, P., Daboul, N., De La Calle, G. M., Delgado, B., Earl, J., El-Shahawy, M. A., Graf, R. J., Greenwood, G., Guevara, A., Wendland, E. M., Mayfield, R. K., Montero, M., Morin, D. J., Narayan, P., Numrungroad, V., Reddy, A. C., Reddy, R., Samson, M. B., Trejo, R., Butcher, M. B., Wise, J. K., Zemel, L. R., Raikhel, M., Weinstein, D., Hernandez, P., Wynne, A., Khan, B. V., Sterba, G. A., Jamal, A., Ross, D., Rovner, S. F., Tan, A., Ovalle, F., Patel, R. J., Talano, J., Patel, D. R., Burgner, A., Aslam, N., Elliott, M., Goral, S., Jovanovich, A., Manley, J. A., Umanath, K., Waguespack, D., Weiner, D., Yu, M., Schneider, L., Jalal, D., Le, T., Nguyen, N., Nguyen, H., Nguyen, D., Nguyen, V., Do, T., Chu, P., Ta, D., Tran, N., Nguyen, D., Pham, B., Pfeffer, M. A., Pocock, S., Swedberg, K., Rouleau, J. L., Chaturvedi, N., Ivanovich, P., Levey, A. S., Christ-Schmidt, H., Held, C., Christersson, C., Mann, J., & Varenhorst, C.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 101
- Issue
- 1
- Pages
- 174-184
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W3200915536
- Cited by
- 92
- References
- 9
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. https://app.cochat.ai/papers/10.1016/j.kint.2021.09.005
- The paper
- Heerspink, H. J. L., Cherney, D., Postmus, D., Stefánsson, B. V., Chertow, G. M., Dwyer, J. P., Greene, T., Kosiborod, M., Langkilde, A. M., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., Toto, R. D., Wheeler, D. C., Heerspink, H. J. L., Wheeler, D. C., Chertow, G., Correa-Rotter, R., . . . Varenhorst, C. (2022). A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International. https://doi.org/10.1016/j.kint.2021.09.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.